Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ROIV

Roivant Sciences Ltd

Dec 26 • 02:18PM ET

12.02

Dollar change +0.02
Percentage change 0.21	%

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: VTI IJH VB XBI XMHQ VXF VBK MDY IJK IBB

Scroll to Statements

Index	-	P/E	2.13	EPS (ttm)	5.66	Insider Own	48.44%	Shs Outstand	733.33M	Perf Week	2.87%
Market Cap	8.75B	Forward P/E	-	EPS next Y	-1.09	Insider Trans	-2.40%	Shs Float	375.36M	Perf Month	-3.49%
Income	4.81B	PEG	-	EPS next Q	-0.25	Inst Own	67.66%	Short Float	11.77%	Perf Quarter	3.93%
Sales	125.68M	P/S	69.65	EPS this Y	-114.65%	Inst Trans	6.71%	Short Ratio	9.09	Perf Half Y	13.77%
Book/sh	7.03	P/B	1.71	EPS next Y	-42.61%	ROA	117.35%	Short Interest	44.20M	Perf Year	4.84%
Cash/sh	7.40	P/C	1.62	EPS next 5Y	-	ROE	159.08%	52W Range	9.69 - 13.06	Perf YTD	7.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.08%	ROI	92.57%	52W High	-7.89%	Beta	1.26
Dividend TTM	-	Quick Ratio	10.43	Sales past 5Y	493.24%	Gross Margin	95.96%	52W Low	24.10%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	10.43	EPS Y/Y TTM	554.70%	Oper. Margin	-895.80%	RSI (14)	51.56	Volatility	2.78% 2.52%
Employees	908	Debt/Eq	0.01	Sales Y/Y TTM	21.84%	Profit Margin	3827.42%	Recom	1.20	Target Price	16.21
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	20.78%	Payout	0.00%	Rel Volume	0.38	Prev Close	12.00
Sales Surprise	-90.26%	EPS Surprise	-15.51%	Sales Q/Q	-87.94%	Earnings	Nov 12 BMO	Avg Volume	4.86M	Price	12.02
SMA20	-0.49%	SMA50	1.07%	SMA200	6.26%	Trades		Volume	1,374,254	Change	0.21%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-03-24 07:00AM	Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
07:00AM	Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
Nov-15-24 05:01PM	Vivek Ramaswamy's Net Worth Is 9 Figures See How the DOGE Co-Lead Made His Millions (Investopedia)
Nov-12-24 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update (GlobeNewswire)
Nov-11-24 07:04AM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
04:35PM	Loading…
Oct-29-24 04:35PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-28-24 09:25AM	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-18-24 07:30AM	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-10-24 06:30AM	Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator (GlobeNewswire)
06:30AM	Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress (GlobeNewswire)
Sep-09-24 07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-04-24 06:55PM	The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy (Yahoo Finance)
Aug-08-24 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update (GlobeNewswire) +6.69%
Jul-25-24 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:53AM	Loading…
May-30-24 11:53AM	ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:20AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update (GlobeNewswire)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-16-24 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 (GlobeNewswire)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
May-07-24 02:04PM	Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare (InvestorPlace)
May-01-24 10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
Apr-25-24 08:00AM	Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis (Business Wire)
Apr-12-24 11:09AM	10 Most Undervalued Stocks to Buy for Under $20 (Insider Monkey)
Apr-02-24 07:00AM	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million (GlobeNewswire)
Mar-27-24 01:55PM	Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck (The Wall Street Journal) +7.54%
Mar-26-24 06:22PM	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 (PR Newswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
07:04AM	Loading…
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Feb-15-24 02:45AM	Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? (Insider Monkey)
Feb-13-24 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update (GlobeNewswire)
Feb-10-24 02:55AM	Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares (GuruFocus.com)
Jan-30-24 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 (GlobeNewswire)
Dec-27-23 08:05PM	5 High Growth International Stocks to Buy (Insider Monkey)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -7.78% +5.82%
Dec-14-23 09:00AM	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire)
02:38AM	5 Stocks Under $20 To Buy Now (Insider Monkey)
Nov-27-23 08:00AM	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus (GlobeNewswire)
Nov-14-23 01:00PM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update (GlobeNewswire)
Nov-10-23 08:00AM	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors (GlobeNewswire)
Oct-30-23 05:30PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 (GlobeNewswire)
Oct-24-23 08:00AM	This $5 Billion Biotech Home Run Took Less Than a Year (The Wall Street Journal)
Oct-23-23 03:02PM	Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion (Investopedia) -11.02%
10:31AM	Why Is Roivant Sciences (ROIV) Stock Up Today? (InvestorPlace)
09:52AM	Roche acquires Telavant, rights to bowel disease drug (Yahoo Finance Video)
06:55AM	Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion (The Wall Street Journal)
03:49AM	Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal (The Wall Street Journal)
01:00AM	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant (GlobeNewswire)
Oct-13-23 08:00AM	Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer (GlobeNewswire)
Oct-05-23 05:01AM	Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com) +5.04%
Oct-03-23 07:00AM	Vivek Ramaswamys Former Company Is Doing Just Fine Without Him (The Wall Street Journal)
Sep-30-23 05:00AM	Insider Sell: President & COO Eric Venker Sells 500,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com)
Sep-26-23 06:00AM	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results (GlobeNewswire) +21.55%
Sep-11-23 08:00AM	Roivant Announces Completion of Redemption of its Outstanding Warrants (GlobeNewswire) -8.65%
Sep-09-23 10:51AM	The Brash Strategy That Made Vivek Ramaswamy a Fortune (The Wall Street Journal)
Aug-17-23 04:05PM	Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants (GlobeNewswire)
Aug-14-23 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update (GlobeNewswire)
Aug-03-23 04:05PM	Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023 (GlobeNewswire)
Aug-02-23 04:05PM	Roivant Announces Redemption of Outstanding Warrants (GlobeNewswire)
Jul-27-23 08:00AM	Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohns Disease (GlobeNewswire)
Jul-26-23 10:21AM	Big Short Steve Eisman Says the Stock Market Will Continue Surging as No Recession Signs Emerge Here Are 2 Stocks That Analysts Like (TipRanks)
Jul-13-23 05:50PM	Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion (The Wall Street Journal)
Jul-11-23 08:00AM	Roivant Ranks No. 25 on Fast Companys Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program (GlobeNewswire)
Jun-28-23 08:57AM	UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update (GlobeNewswire) +11.27%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update (GlobeNewswire)
Jun-26-23 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023 (GlobeNewswire) -6.33%
Jun-22-23 07:30AM	Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period (GlobeNewswire)
Jun-21-23 05:00PM	Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis (GlobeNewswire)
May-16-23 07:00AM	Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old (GlobeNewswire)
Apr-04-23 07:37AM	Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory (Business Wire)
07:37AM	Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research (Business Wire)
Mar-28-23 08:00AM	Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients (GlobeNewswire)
Mar-15-23 07:45AM	Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old (GlobeNewswire) +7.91%
Mar-14-23 04:07PM	Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis (GlobeNewswire)
08:00AM	Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs (GlobeNewswire)
Mar-07-23 08:00AM	Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement (GlobeNewswire)
Feb-21-23 08:32PM	Roivant Sciences Announces Change to its Board of Directors (GlobeNewswire)
Feb-13-23 04:17PM	Collecting Pharmas Scraps Can Pay Off for This Biotech (The Wall Street Journal) +7.77%
07:00AM	Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update (GlobeNewswire)
Feb-02-23 09:14PM	Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares (GlobeNewswire) -11.12%
Feb-01-23 04:05PM	Roivant Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Jan-30-23 08:00AM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023 (GlobeNewswire)
Jan-04-23 06:05AM	Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations (GlobeNewswire) +5.73%
Dec-07-22 06:30AM	Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant (PR Newswire)
Dec-01-22 08:00AM	Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases (GlobeNewswire) +8.21%
Nov-14-22 07:00AM	Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update (GlobeNewswire)
Nov-10-22 09:00AM	Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC (GlobeNewswire)
Nov-08-22 06:15AM	Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering (GlobeNewswire) -11.19%
Nov-07-22 04:01PM	Roivant Sciences Announces Proposed Public Equity Offering (GlobeNewswire)
Oct-18-22 04:00PM	Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences (GlobeNewswire) -5.74%
Aug-30-22 07:00AM	Roivant to Participate in September Investor Events (GlobeNewswire)
Aug-16-22 11:44AM	Time To Worry? Analysts Are Downgrading Their Roivant Sciences Ltd. (NASDAQ:ROIV) Outlook (Simply Wall St.)
Aug-15-22 07:00AM	Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update (GlobeNewswire)
Aug-14-22 10:53AM	Investors in Roivant Sciences (NASDAQ:ROIV) from a year ago are still down 56%, even after 16% gain this past week (Simply Wall St.)
Aug-03-22 07:00AM	Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022 (GlobeNewswire)
Jul-23-22 09:00AM	Roivant Sciences Ltd.'s (NASDAQ:ROIV) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sukhatme Mayukh	Officer	Dec 24 '24	Proposed Sale	12.00	185,946	2,231,700		Dec 26 08:02 AM
Sukhatme Mayukh	Officer	Dec 23 '24	Proposed Sale	12.00	10,796	129,555		Dec 23 04:21 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 18 '24	Option Exercise	3.85	412,584	1,588,448	19,249,131	Dec 20 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 18 '24	Sale	12.05	412,584	4,971,637	18,836,547	Dec 20 09:00 PM
Venker Eric	Officer	Nov 20 '24	Proposed Sale	11.49	100,000	1,148,554		Dec 20 04:29 PM
Sukhatme Mayukh	Officer	Dec 18 '24	Proposed Sale	12.05	412,584	4,969,631		Dec 18 04:33 PM
Venker Eric	President & COO	Nov 20 '24	Option Exercise	3.85	100,000	385,000	706,525	Nov 22 09:00 PM
Venker Eric	President & COO	Nov 20 '24	Sale	11.32	100,000	1,132,000	606,525	Nov 22 09:00 PM
Venker Eric	Officer	Nov 20 '24	Proposed Sale	11.32	100,000	1,132,008		Nov 20 04:45 PM
Venker Eric	President & COO	Oct 21 '24	Option Exercise	3.85	100,000	385,000	717,470	Oct 22 09:00 PM
Venker Eric	President & COO	Oct 21 '24	Sale	11.65	100,000	1,165,000	617,470	Oct 22 09:00 PM
Venker Eric	Officer	Oct 21 '24	Proposed Sale	11.65	100,000	1,165,393		Oct 21 04:45 PM
QVT Financial LP	Director by Deputization	Sep 26 '24	Sale	11.82	876,000	10,354,320	22,179,358	Sep 26 09:22 PM
QVT Financial LP	Director by Deputization	Sep 25 '24	Sale	11.77	50,000	588,500	23,055,358	Sep 26 09:22 PM
MANCHESTER KEITH S	Director	Sep 24 '24	Sale	11.62	368,052	4,278,604	1,412,126	Sep 26 08:35 PM
MANCHESTER KEITH S	Director	Sep 25 '24	Sale	11.77	134,948	1,587,704	1,277,178	Sep 26 08:35 PM
Gold Daniel Allen	Director	Sep 24 '24	Sale	11.62	1,565,670	18,200,914	5,723,423	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 25 '24	Sale	11.77	991,593	11,666,389	4,731,830	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 26 '24	Sale	11.82	876,000	10,354,320	22,179,358	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 24 '24	Sale	11.62	577,186	6,709,787	2,079,059	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 25 '24	Sale	11.77	415,551	4,889,317	1,713,508	Sep 26 08:34 PM
BNEI ZAHAV LLC	Director	Sep 25 '24	Proposed Sale	11.76	23,917	281,264		Sep 25 04:30 PM
RIOJA DOLCE LLC	Director	Sep 25 '24	Proposed Sale	11.76	170,817	2,008,808		Sep 25 04:25 PM
KEITH S MANCHESTER REVOCABLE T	Director	Sep 25 '24	Proposed Sale	11.76	134,948	1,586,988		Sep 25 04:23 PM
RIOJA LIETO LLC	Director	Sep 25 '24	Proposed Sale	11.76	170,817	2,008,808		Sep 25 04:20 PM
DANIEL GOLD & LAURA GOLD	Director	Sep 25 '24	Proposed Sale	11.76	991,593	11,661,134		Sep 25 04:19 PM
Gline Matthew	CEO	Sep 23 '24	Option Exercise	3.85	1,550,000	5,967,500	19,853,800	Sep 24 09:01 PM
Gline Matthew	CEO	Sep 23 '24	Sale	11.79	1,983,257	23,382,600	17,870,543	Sep 24 09:01 PM
Kumar Rakhi	Chief Accounting Officer	Sep 23 '24	Option Exercise	3.85	250,000	962,500	459,322	Sep 24 09:01 PM
Kumar Rakhi	Chief Accounting Officer	Sep 23 '24	Sale	11.89	250,000	2,972,500	209,322	Sep 24 09:01 PM
DANIEL GOLD &LAURA GOLD JT TEN	Director	Sep 24 '24	Proposed Sale	11.62	1,565,670	18,200,914		Sep 24 07:53 PM
RIOJA LIETO LLC	Director	Sep 24 '24	Proposed Sale	11.63	269,712	3,135,402		Sep 24 07:52 PM
RIOJA DOLCE LLC	Director	Sep 24 '24	Proposed Sale	11.63	269,712	3,135,402		Sep 24 07:51 PM
BNEI ZAHAV LLC	Director	Sep 24 '24	Proposed Sale	11.62	37,762	438,983		Sep 24 07:48 PM
KEITH S MANCHESTER REVOCABLE T	Director	Sep 24 '24	Proposed Sale	11.63	368,052	4,281,550		Sep 24 07:43 PM
Gline Matthew	Officer	Sep 23 '24	Proposed Sale	11.79	1,983,257	23,383,088		Sep 23 04:53 PM
Kumar Rakhi	Officer	Sep 23 '24	Proposed Sale	11.89	250,000	2,972,360		Sep 23 04:47 PM
Venker Eric	President & COO	Feb 09 '24	Option Exercise	3.85	96,950	373,258	629,157	Feb 09 09:00 PM
Venker Eric	President & COO	Feb 09 '24	Sale	10.92	96,950	1,058,694	532,207	Feb 09 09:00 PM
Ramaswamy Vivek	10% Owner	Jan 02 '24	Sale	11.05	3,000,000	33,150,000	51,929,426	Jan 03 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ROIV

Roivant Sciences Ltd

Upgrade your FINVIZ experience